American driver Jak Crawford will be Aston Martin's third driver for the 2026 Formula 1 season, effectively acting as reserve to Fernando Alonso and Lance Stroll should either be unable to race.

For much of the 2025 season, Jak Crawford has been considered the next American hopeful for Formula One. The last American to compete in the pinnacle of motorsport was Logan Sargeant, who raced for ...

AUSTIN -- Rising American racing star Jak Crawford will drive in first practice for Aston Martin ahead of Formula 1's Mexico City Grand Prix next week. Crawford, 20, will take Lance Stroll's seat in ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for cases where a patient may not be appropriate for a TNF blocker, drugmaker ...

Jak Roberto clarified that he is not courting his "My Father's Wife" co-star Kylie Padilla. The Sparkle star guested on "Fast Talk with Boy Abunda" Friday where he was candidly asked by Tito Boy if he ...

A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...

Maddie Fisher is a writer, journalist and game developer. She was born and raised on the east coast, having started working in games journalism over fifteen years ago. She tends to enjoy musical ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

Jake brings two decades of experience with him, having covered major industry events, breaking news, one-on-one interviews, and more. When he's not playing World of Warcraft, he's usually on the hunt ...

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching a 2028 ...